Nektar Therapeutics Stock Price - NKTR

-22.05 (-100.00%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Nektar Therapeutics NKTR NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 22.05 0.00 0.00 0.00 22.05 04:00:00
Bid Price Ask Price Spread Spread % News
19.00 26.50 7.50 28.3% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

Nektar Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.88B 175.92M $ 681.31M 3.61 - 172.11M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Nektar Therapeutics News

Loading Messages....

Latest NKTR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical NKTR Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week22.6724.0022.0023.001,776,759-0.62-2.73%
1 Month22.5524.0019.5621.801,574,001-0.50-2.22%
3 Months20.5329.0018.6822.772,242,0581.527.4%
6 Months18.3129.0015.63519.782,890,4143.7420.43%
1 Year42.1744.0615.63524.092,403,071-20.12-47.71%
3 Years13.13111.3612.5042.372,368,6838.9267.94%
5 Years13.65111.369.1634.511,943,8868.4061.54%

Nektar Therapeutics Description

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Your Recent History
Nektar The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.